Navigation Links
RNAi Gene Silencing System

Gene silencing by RNA interference (RNAi) in eukaryotic cell cultures requires double-stranded molecules known as short interfering RNA (siRNA). QIAGEN is a licensed supplier of siRNA, offering a custom siRNA oligonucleotide synthesis service, library siRNA directed against common target genes, and a Cancer siRNA Oligo Set for screening a large number of cancer-related genes using RNAi techniques. Features and benefits
  • siRNA synthesis using patented TOM-Amidite chemistry for high-coupling efficiency
  • High-purity siRNA for efficient gene silencing
  • Expert advice on siRNA design for maximizing gene-silencing potential
  • Labeled siRNA allowing transfection to be easily followed
  • siRNA is annealed and ready-to-use in cell transfection
Principle The application of RNAi to mammalian cells has revolutionized the field of functional genomics by allowing targeted inhibition of gene expression using double-stranded RNA (dsRNA) that carries the same sequence as mRNA transcribed from the target gene. In mammalian cell systems, double-stranded siRNA oligos can be used to induce gene silencing.

After siRNAs are delivered to the cytoplasm of a cell, they bind to a multi-protein complex to form an RNA-induced silencing complex (RISC). The siRNA-protein complex targets en dogenous mRNA whose sequence matches that of the siRNA. The RISC nuclease activity then cleaves the mRNAsiRNA duplex resulting in silencing of the target gene (see flowchart "siRNA-Mediated RNAi").

To target a specific gene by RNAi, a double-stranded siRNA containing the sense and antisense sequence of mRNA transcribed from the gene is required. QIAGEN provides expert advice on siRNA design. Patented TOM-Amidites are used to synthesize high-quality, high-purity, 21-nucleotide sense and antisense RNA oligonucleotides that are annealed to produce a duplex with symmetric 2-nucleotide 3'-end overhangs. Deprotected siRNA duplexes are desalted and purified to >97% purity by HPLC (ultrapure) or 80-85% (crude option). siRNA is supplied with a sterile resuspension buffer and is ready to use in transfection procedures.

Efficient Gene Silencing Using QIAGEN siRNA and TransMessenger Reagent Western blot of extracts from transfected HeLa-S3 cells probed with lamin A/C monoclonal primary antibodies. Cells were transfected using the indicated reagents. siRNA: short interfering RNA duplex targeting lamin A/C at position 608630 relative to the start codon; TM: TransMessenger Transfection Reagent; ODN: Scrambled 24mer oligodeoxynucleotide (control).

Applications
  • Repress expression of endogenous genes
  • Study of molecular and cellular processes
  • Target validation studies
  • Potential for gene therapy
Efficient, Targeted Gene Silencing Relative expression levels of lamin A/C after siRNA transfection. The value for the mock transfection was set as 1. Data were normalized to the expression level of GAPDH (internal control), which was quantified by real-time RT-PCR using Omniscript Reverse Transcriptase and the QuantiTect SYBR Green PCR Kit. Expression levels were calculated using a standard curve generated using different amounts of HeLa S3 cDNA. Data obtained under the indicated transfection conditions are shown as relative, normalized expression levels. Total RNA was prepared using the RNeasy Mini Kit and the QIAShredder homogenizer.



'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. Quantification of siRNA Silencing Efficiency Using the LightCycler System
2. Measuring Gene Silencing Effects by RT-PCR Without RNA Isolation
3. Drive Long-Term Silencing with CMV Vectors
4. Enhanced siRNA Delivery and Long-term Gene Silencing
5. Fast, Accurate Assessment of siRNA-induced Gene Silencing
6. Superior Gene Silencing Using Adenoviral Vectors
7. Your Data: Silencing Hepatitis C Virus Replication With In Vitro Transcribed siRNAs
8. YOUR DATA: Direct Real-time RT-PCR on Sympathetic Neuron Lysates Silencing of Focal Adhesion Kinases with Silencer Validated siRNAs
9. YOUR DATA: Direct Real-time RT-PCR on Sympathetic Neuron Lysates Silencing of Focal Adhesion Kinases with Silencer Validated siRNAs
10. Your Data: Silencing Neural Cell Adhesion Genes with In Vitro Transcribed siRNAs
11. Your Data: Silencing of a Pro-apoptotic Transcription Factor Using Synthetic siRNA
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... CA (PRWEB) , ... December 01, 2016 , ... ACEA ... from its Phase I/II clinical trials for AC0010 at the World Conference on Lung ... to providing an update on the phase I/II clinical trials for AC0010 in patients ...
(Date:12/2/2016)... KING OF PRUSSIA, PA (PRWEB) , ... December 01, 2016 , ... ... clinical research is through industry-wide collaboration, standardization and a beautiful technology experience. All three ... which convened more than 100 clinical trial leaders from over 40 sponsor, CRO and ...
(Date:12/2/2016)... -- The immunohistochemistry (IHC) market is projected to ... 7.3% during the forecast period of 2016 to 2021 dominated by ... for the largest share of immunohistochemistry (IHC) market, by end user. ... , , ... spread across 225 pages, profiling 10 companies and supported with 181 ...
(Date:11/30/2016)... , Nov. 30, 2016 /PRNewswire/ - Portage Biotech ... Securities Exchange: PBT.U), is excited to announce the ... focused on developing preclinical ophthalmology assets through proof ... potent anti-inflammatory created by Portage Pharmaceuticals Limited and ... with ocular surface and anterior segment diseases. This ...
Breaking Biology Technology:
(Date:11/22/2016)... , Nov. 22, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... LiveWire Healthcare and Life Sciences Awards as "Most ... off an unprecedented year of recognition and growth for ... over 15 years. iMedNet ™ ...
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
Breaking Biology News(10 mins):